article
Refining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
List view / Grid view
Cancer
news
AI-designed CDK12/13 inhibitors target resistant cancers
Insilico Medicine’s AI-designed CDK12/13 inhibitors show promise against treatment-resistant cancers. Find out how this breakthrough could reshape cancer therapy.
news
Leukaemia cells hit hard by innovative dual-drug approach
Scientists have discovered a dual-drug therapy that dramatically increases leukaemia cell death, offering new hope for patients with acute myeloid leukaemia (AML). By combining SRC and MCL-1 inhibitors, this approach opens the door to more effective treatments.
news
New predictive model identifies synergistic drug pairings
Researchers at Mount Sinai have created a computational tool that predicts effective drug combinations, providing a faster and more cost-efficient method for identifying potential treatments for complex diseases like cancer.
news
New enzyme discovery could boost cancer immunotherapy
A new discovery from the University of Geneva highlights the crucial role of the CH25H enzyme, which is found in cancerous lymphatic cells. This enzyme plays a key part in activating immune cells, opening up a promising pathway for improving the success of cancer immunotherapies.
news
AI designs peptides for ‘undruggable’ diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
whitepaper
Beyond the Lab: Stem cell research
Download our latest report to discover how stem cell research is revolutionising treatments for chronic diseases, cancer and regenerative medicine.
article
FDA’s Project Optimus: A new era in oncology drug dosing
Explore how FDA’s Project Optimus is reshaping oncology drug dosing strategies, with insights on precision medicine, adaptive trial designs, and the role of CROs in optimising patient outcomes.
article
Obstacles and innovations of macrocyclic drug development
Macrocycles outperform traditional therapeutics on several fronts, yet they account for just four percent of FDA-approved drugs. Colleagues Ann E Cleves and Ajay N Jain from Optibrium Ltd explain why we can expect to see this number increase in the coming years.
news
New insights into adhesion GPCRs spark drug design potential
Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments.
news
PHC Corporation to present LiCellGrow at Advanced Therapies Week 2025
The LiCellGrow cell expansion system enables real-time metabolic monitoring and automated culture optimisation to accelerate cell and gene therapy manufacturing.
article
New research improves the safety and effectiveness of ADC cancer treatments
Learn how the University at Buffalo is pioneering safer, more effective ADC therapies.
article
How AI will reshape pharma in 2025
AI is set to transform drug development in 2025, streamlining processes and opening new possibilities. Learn how this technology is transforming clinical trials and reshaping the pharmaceutical industry.
news
Tessera’s gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
news
Cancer Research Horizons collaborates with Diamond to accelerate drug discovery
Cancer Research Horizons has teamed up with Diamond Light Source to drive the discovery of new cancer treatments.
